AstraZeneca PLC (AZN)
-NYSE 50.19 
0.79(1.55%) 04:00 SGT|After Hours
:
50.19 0.00 (0.00%) 05:26 SGT
| Prev Close: | 50.98 |
|---|
| Open: | 50.89 |
|---|
| Bid: | 50.00 x 400 |
|---|
| Ask: | 52.90 x 100 |
|---|
| 1y Target Est: | 47.58 |
|---|
| Beta: | 0.55 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 50.18 - 50.99 |
|---|
| 52wk Range: | 42.68 - 53.45 |
|---|
| Volume: | 1,171,019 |
|---|
| Avg Vol (3m): | 2,075,320 |
|---|
| Market Cap: | 62.74B |
|---|
| P/E (ttm): | 11.10 |
|---|
| EPS (ttm): | 4.52 |
|---|
| Div & Yield: | 3.80 (7.50%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Will Amarin's Fish Oil Drug Slip Past the FDA a Second Time?at Motley Fool(Thu, 07:08 SGT)
- 3 Drug Stocks Poised To Move As Bears Attackat TheStreet(Thu, 05:26 SGT)
- Wal-Mart’s Online Battle, AstraZeneca Diabetes Drug Falls Through, and 3 More Hot Stocksat Wall St. Cheat Sheet(Thu, 01:41 SGT)
- Top Line Results: No Cardiovascular Benefits Found For Saxagliptinat Forbes(Thu, 01:27 SGT)
- An AstraZeneca And Bristol-Myers Diabetes Trial Is A Dudat Forbes(Thu, 01:25 SGT)
- Study: no new benefits for diabetes drug OnglyzaAP(Wed, 19 Jun)
- AstraZeneca in $560 m deal for respiratory firmAP(Mon, 10 Jun)
- Bristol-Myers, AstraZeneca get faster FDA reviewAP(Wed, 5 Jun)
- AstraZeneca to pay about $260M for Omthera PharmaAP(Wed, 29 May)
- Amarin slumps as AstraZeneca buys potential rivalAP(Wed, 29 May)
Key Statistics
| Forward P/E (1 yr): | 9.73 |
|---|
| P/S (ttm): | 2.36 |
|---|
| Ex-Dividend Date: | 13-Feb-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.35 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.23 |
|---|
| Mean Recommendation*: | 3.4 |
|---|
| PEG Ratio (5 yr expected): | -1.00 |
|---|
Business Summary
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide.
View More